<DOC>
	<DOCNO>NCT00375999</DOCNO>
	<brief_summary>1.Study rationale : There standard regimen advance and/or metastatic gastric cancer patient relapse adjuvant chemotherapy fail first systemic chemotherapy . 2.Primary Objectives : To evaluate overall response rate accord Response Evaluation Criteria Solid Tumors criterion To investigate time response 3.Design : single-center , Open label , Phase II study . docetaxel 75mg/m2 administered day 1 intravenously combine intravenous Epirubicin 60mg/m2 give day 2 every 3 week . 4.Primary endpoint : 1 . Efficacy : overall response rate accord Response Evaluation Criteria Solid Tumors criterion , time response , duration response , time treatment failure . 2 . Safety-Adverse event laboratory test , grade accord NCI Common Toxicity Criteria Adverse Effects ( version 3.0 ) .</brief_summary>
	<brief_title>Docetaxel Epirubicin Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Male female outpatient ≥ 18 year , Eastern Cooperative Oncology Group performance status 1 , histologically confirm gastric adenocarcinoma inoperable and/or metastatic disease . Patients must least one target lesion minimum lesion size per Response Evaluation Criteria Solid Tumors criterion ( least 1 unidimensional measurable lesion ≥ 20 mm diameter conventional CT MRI scan , ≥ 10 mm diameter spiral CT scan ) . Creatinine clearance ≥ 60ml/min ( estimate creatinine clearance must calculate baseline patient . ) Adequate major organ function : Hematopoietic function : white blood cell &gt; 4,000/mm3 absolute neutrophil count &gt; 2,000/mm3 , Platelet count ≥ 100,000/mm3 , Hepatic function : Bilirubin &lt; 1.5 X upper normal limit , aspartate aminotransferase/alanine aminotransferase level &lt; 2.5 X upper normal limit , alkaline phosphatase &lt; 5 x upper normal limit ( except case bone metastasis without liver disease ) Renal function : Creatinine &lt; 1 x upper normal limit creatinine clearance ≥ 60ml/min . Patients must previously receive systemic treatment ( cytotoxic chemotherapy active/passive immunotherapy ) advance metastatic disease . Adjuvant neoadjuvant treatment nonmetastatic ( M0 ) disease allow complete least 6 month prior initiation study treatment . The following laboratory value : neutrophil ≤1.5 X 109 /L , platelet count &lt; 100 X 109 /L serum bilirubin ≥ 1.5 X upper normal limit , aspartate aminotransferase , alanine aminotransferase &gt; 2.5 X upper normal limit &gt; 5 X upper normal limit case liver metastasis Alkaline phosphatase &gt; 2.5 X upper normal limit 5 X upper normal limit case liver metastases &gt; 10 X upper normal limit case bone disease . Prior therapy Taxotere Epirubicin exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>